Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corp (ICU) is a medical technology innovator developing extracorporeal therapies to combat hyperinflammation's impact on vital organs. This page serves as the definitive source for verified company news and regulatory developments.
Investors and healthcare professionals will find timely updates on clinical trial progress, FDA regulatory milestones, and strategic partnerships shaping the future of inflammation management. Our curated news collection covers essential developments including product innovations, research collaborations, and market expansion efforts.
All content undergoes rigorous verification to ensure accuracy regarding SeaStar Medical's patented technologies and their clinical applications. Regular updates provide insights into the company's progress in commercializing therapies that target cytokine storms and immune system modulation.
Bookmark this page for streamlined access to breaking news about ICU's medical device advancements, peer-reviewed research findings, and healthcare sector initiatives. Check back frequently for objective reporting on developments impacting both patient care and investment considerations.
SeaStar Medical Holding Corporation (Nasdaq: ICU) has activated its first clinical site, Good Samaritan Regional Medical Center in Oregon, for the pivotal NEUTRALIZE-AKI trial. This trial aims to evaluate the Selective Cytopheretic Device (SCD) therapy's effectiveness for critically ill adults suffering from acute kidney injury (AKI). The SCD, which recently received FDA Breakthrough Device Designation, targets inflammation to potentially reduce mortality and dialysis dependency. The trial anticipates enrolling up to 200 patients across 30 U.S. sites, with primary endpoints focusing on 90-day mortality and dialysis dependency. Previous studies indicated up to 50% reduction in mortality among patients using the SCD, highlighting its promise in improving patient outcomes.
FAQ
What is the current stock price of SeaStar Medical Holding (ICU)?
What is the market cap of SeaStar Medical Holding (ICU)?
